Table IV.
Summary of studies examining treatment of relapsed mantle cell lymphoma.
| Year | Author | Experimental treatment |
n | ORR | Median TTF (months) |
Median OS (months) |
|---|---|---|---|---|---|---|
| 2010 | Ohmachi | Bendamustine | 11 | 100% | NR | NA |
| 2005 | Rummel | B-R | 16* | 75% | 18 (PFS) | NR |
| 2008 | Robinson | B-R | 12 | 92% | 19.0 (DOR) | NA |
| 2011 | Warsch† | B-R | 25 | 80% | 13.4 | NR |
| 2007 | Weide | B-R-mitoxantrone | 18 | 78% | 21.0 (PFS) | 31 |
| 2011 | Friedberg | B-R-bortezomib | 7 | 71% | NA | NA |
| 2001 | Cohen | FC | 30‡ | 63% | 4.8 (FFS) | 17.5 |
| 2004 | Forstpointer | R-FCM | 52 | 52% | 8.0 (PFS) | NR |
| 2005 | Witzig | Temsirolimus | 35 | 38% | 6.5 (TTP) | 12 |
| 2009 | Hess | Temsirolimus | 54§ | 22% | 4.8 (PFS) | 12.8 |
| 2009 | Habermann | Lenalidomide | 15 | 53% | 5.6 (PFS) | NA |
| 2008 | O’Connor | Bortezomib | 40 | 47% | 5.3 (PFS) | NA |
| 2009 | Goy | Bortezomib | 141 | 40% | 6.7 (TTP) | 23.5 |
*
Seven of the 16 patients in this study had refractory MCL.
†
Present study.
‡
Twenty of the 30 patients in this study had relapsed/refractory MCL.
§
Outcomes shown for the 54 patients allocated to 175/75 mg dosing schedule.
MCL, mantle cell lymphoma; B-R, bendamustine, rituximab; FC, fludarabine, cyclophosphamide; R-FCM, rituximab, fludarabine, cyclophosphamide, mitoxantrone; ORR, overall response rate; TTF, time to treatment failure; NR, not reached; PFS, progression-free survival; DOR, duration of response; NA, data not available; FFS, failure-free survival; TTP, time to progression; OS, overall survival.